Vetter Expands Global Clinical Manufacturing Network in U.S. and Europe

Vetter, a global Contract Development and Manufacturing Organization (CDMO), continues to expand its global clinical manufacturing network in the U.S. and Europe with the ongoing scale-up of its Vetter Development Service offering.

Expanding U.S. Presence

Vetter’s site in Skokie, Illinois continues to serve as a cornerstone for global biotech partners in their journeys through clinical development. To build on this foundation, construction of Vetter’s new 160,000-square-foot facility in Des Plaines, Illinois, is currently advancing on schedule. With the steel structure nearly completed, interior work is set to begin soon. When operational in 2029, the site will expand Vetter’s U.S. clinical manufacturing capabilities and reinforce its long-term commitment to growth and serving patients.

European Site Scales for Customer Demand

Vetter’s European clinical facility in Rankweil, Austria, has also achieved a new level of operational maturity to support the increasing complexities of drug product development. To accommodate steadily rising project volumes, the company is making several infrastructure enhancements at the site designed to increase capacity and streamline processes for the production of human Investigational Medicinal Products.

These improvements include the implementation of a new weighing room, an additional compounding room within the aseptic production area, and increased capacity for manual visual inspection. In addition, the site will benefit from new cold-storage rooms, specialized freezer units for API storage, and an additional incubator chamber to strengthen microbiological testing capabilities.

“Our continued global expansion reflects our holistic approach to supporting our customers with their clinical development,” said Dr. Claus Feussner, SVP of Vetter Development Service. “By investing in both technology and capacity, we are working to provide our partners with the tailored early-stage manufacturing services they need for their molecules to progress from the lab to the clinic.”